To truly excel in translating biomedical research, one ideally has the business acumen to drive commercialisation but also a deep understanding of the science behind a novel therapy,
The CCRM Australia Clarity Unit will adopt an academic focus that will provide market research and reporting to accumulate thought leadership and analysis - to facilitate the commercialisation
The two-day in-person symposium will be held on October 21 and 22 at the QIMR-Berghofer Institute of Medical Research and will be specifically focused on the challenges of
Cartherics Pty Ltd (“Cartherics”) and the Australian Regenerative Medicine Institute, including commercialisation initiative CCRM Australia, announced agreements for closer cooperation and collaboration today. “Cartherics affiliation with ARMI is
A participatory discussion with key exosome stakeholders and the regulatory requirements for exosome therapies. CCRM Australia is organising a series of workshops that seek to encourage dialogue between
CCRM Australia proposes a more pro-active intellectual property policy as an option to unlock Australia’s best-protected treasure trove. CCRM Australia was one of many organisations that submitted a
Regenerative medicine is no longer an obscure concept. With major translational milestones in recent years, from the rollout of CAR-T therapies to the emerging commercialisation of tissue engineering
CCRM Australia looks to the new decade with Australia as part of a worldwide regenerative medicine network without borders The coming decade is likely to bring significant advances
How CCRM Australia’s academic and industry partnerships helped an industry innovator connect with academic expertise and resources to deliver commercial-scale cell manufacturing. About Cynata Cynata is an Australian
